| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T132 |
0-2 |
Sentence |
denotes |
5. |
| T133 |
4-14 |
Sentence |
denotes |
Conclusion |
| T134 |
15-215 |
Sentence |
denotes |
In summary, inefficient data sharing, irreproducibility of published work, high cost, high failure rates, and slow pace remain as significant challenges for the drug discovery and development process. |
| T135 |
216-495 |
Sentence |
denotes |
Over the past few years, many research institutions around the world have developed an infrastructure in collaboration with pharma companies, peer research laboratories/institutions, government/philanthropy organizations to crowdsource resources, share knowledge and assess risk. |
| T136 |
496-659 |
Sentence |
denotes |
The idea was mooted with the formation of the Academic Drug Discovery Consortium (ADCC) that aims at nurturing the academic drug discovery centers in the USA [46]. |
| T137 |
660-850 |
Sentence |
denotes |
ADCC initiated a collaborative network to facilitate exchange of expertise and technical know-how, and the formation of partnerships among the participating organizations including industry. |
| T138 |
851-1083 |
Sentence |
denotes |
In addition to academic drug discovery centers, independent researchers around the globe have registered from various organizations, including universities, pharmaceutical companies, government institutions and diseases foundations. |
| T139 |
1084-1200 |
Sentence |
denotes |
Many companies have also approached the ADDC for assistance in designing specific disease/ drug research areas [46]. |
| T140 |
1201-1396 |
Sentence |
denotes |
The success of ADCC emphasizes the need for networking/ collaboration to harness the best possible avenues in the most cost-effective way for the rapid discovery of novel and effective medicines. |
| T141 |
1397-1554 |
Sentence |
denotes |
Very recently, an unprecedented effort, as ever in the history, has been made to avert the COVID-19 pandemic by the National Institutes of Health (NIH) [47]. |
| T142 |
1555-1713 |
Sentence |
denotes |
The NIH in collaboration with major drug companies and funders has announced a plan to conduct clinical trials employing drugs and vaccines to treat COVID-19. |
| T143 |
1714-1863 |
Sentence |
denotes |
Priorities have been designated for testing and development of selected drugs/vaccines to avoid duplication and wastage of time, money and resources. |
| T144 |
1864-2128 |
Sentence |
denotes |
The partnership called Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) is a collaborative network of NIH, government agencies in the U.S, pharma/biotech companies, academia and nonprofit Foundations of the National Institutes of Health (FNIH). |
| T145 |
2129-2284 |
Sentence |
denotes |
ACTIV is defined as an international strategy to evaluate data on most promising early drug candidates for clinical trials by efficient use of NIH funding. |
| T146 |
2285-2487 |
Sentence |
denotes |
The alliance will also study and analyze the genome of all SARS-CoV-2 strains, and how the virus infects various cell types and patients with different, underlining conditions, ages and genetic makeups. |
| T147 |
2488-2586 |
Sentence |
denotes |
This is what the whole world looks forward to, a global alliance for the benefit of the humankind. |
| T148 |
2587-2778 |
Sentence |
denotes |
Public–private partnerships, adaptive trial designs, and big data offers excellent avenues for innovating drug discovery and design process but face several challenges which must be met [27]. |
